Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials

22 recruitingLast updated: June 18, 2026

There are 22 actively recruiting idiopathic pulmonary fibrosis (ipf) clinical trials across 22 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 1. Top locations include Winston-Salem, North Carolina, United States, Birmingham, Alabama, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Idiopathic Pulmonary Fibrosis (IPF) Trials at a Glance

22 actively recruiting trials for idiopathic pulmonary fibrosis (ipf) are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Winston-Salem, Birmingham, and Philadelphia. Lead sponsors running idiopathic pulmonary fibrosis (ipf) studies include Avalyn Pharma Inc., Hospital de Granollers, and Azienda Unita Sanitaria Locale di Piacenza.

Browse idiopathic pulmonary fibrosis (ipf) trials by phase

Treatments under study

About Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials

Looking for clinical trials for Idiopathic Pulmonary Fibrosis (IPF)? There are currently 27 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic Pulmonary Fibrosis (IPF) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic Pulmonary Fibrosis (IPF) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics120 enrolled16 locationsNCT06968845
Recruiting
Phase 2

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Dragonboat Biopharmaceutical Company Limited96 enrolled1 locationNCT07447102
Recruiting
Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Mannkind Corporation24 enrolled9 locationsNCT07344558
Recruiting
Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.340 enrolled52 locationsNCT06951217
Recruiting
Phase 3

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

Idiopathic Pulmonary Fibrosis (IPF)
Sunshine Lake Pharma Co., Ltd.472 enrolled1 locationNCT07082842
Recruiting
Not Applicable

Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial

Fibrotic interstitial lung diseaseInterstitial Lung Disease (ILD)Idiopathic Pulmonary Fibrosis (IPF)+2 more
Hospital de Granollers92 enrolled1 locationNCT07482917
Recruiting
Not Applicable

Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

Progressive Pulmonary FibrosisFibrotic interstitial lung diseaseInterstitial Lung Disease (ILD)+2 more
Hospital de Granollers152 enrolled1 locationNCT07486206
Recruiting
Phase 2

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.160 enrolled3 locationsNCT07194382
Recruiting
Not Applicable

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Fibrotic Interstitial Lungs Diseases
Katerina M. Antoniou100 enrolled1 locationNCT07466420
Recruiting
Phase 3

A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)
Beijing Tide Pharmaceutical Co., Ltd508 enrolled1 locationNCT07464912
Recruiting
Phase 2

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB360 enrolled117 locationsNCT06588686
Recruiting
Phase 2

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Shanghai Synvida Biotechnology Co.,Ltd.48 enrolled12 locationsNCT07121413
Recruiting

A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Royal Brompton & Harefield NHS Foundation Trust30 enrolled1 locationNCT07332117
Recruiting
Phase 2

SB17170 Phase 2 Trial in IPF Patients

Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)IPF
SPARK Biopharma30 enrolled5 locationsNCT06747923
Recruiting

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

SmokingSmoking CessationChronic Obstructive Pulmonary Disease (COPD)+3 more
Weill Medical College of Cornell University2,000 enrolled1 locationNCT01776398
Recruiting
Phase 2

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
InSilico Medicine Hong Kong Limited40 enrolled12 locationsNCT05975983
Recruiting

Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography

Connective Tissue Disease (CTD)Interstitial Lung Disease Due to Systemic Disease (Disorder)Idiopathic Pulmonary Fibrosis (IPF)+1 more
Azienda Unita Sanitaria Locale di Piacenza500 enrolled5 locationsNCT07174102
Recruiting
Not Applicable

Downhill Walking in IPF

Idiopathic Pulmonary Fibrosis (IPF)
Saglik Bilimleri Universitesi34 enrolled1 locationNCT06756230
Recruiting

D Vitamin and Alveolar Macrophages in Idiopathic Pulmonal Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
University of Aarhus120 enrolled1 locationNCT06909409
Recruiting

The Genetics of Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
University of Colorado, Denver1,000 enrolled1 locationNCT03478553